## Review setup
- **Input scope** Full manuscript text (abstract, background, methods, results, discussion, conclusion) as provided
- **Assessment boundary** Scientific soundness, methodological rigor, validity of claims, and alignment with Nature-style criteria based solely on the supplied material
- **Shared manuscript claim summary** The authors predict a 3D structure of the PfAP2-I transcription factor using ab initio methods, validate it, identify five small-molecule hits via pharmacophore-based virtual screening and molecular docking, and propose MCULE-7146940834 as a lead candidate based on binding affinity, drug-likeness, toxicity predictions, and molecular dynamics simulation stability.
- **Visible evidence base** Abstract; Background; Methods sections for structure prediction, validation, active site prediction, virtual screening, docking, drug-likeness/toxicity, and MD simulation; Results sections for structure prediction, validation, active site prediction, docking, and MD simulation; Discussion; Conclusion; references to supplementary tables and figures (not provided)
- **Missing materials affecting confidence** Supplementary Tables 1–4, all figures (Figures 1–8), full docking results for all 8115 compounds, MD simulation trajectory data, force field parameters, and validation output details (e.g., ERRAT plots, Ramachandran plots, MolProbity full reports) are not provided. These are essential for independent verification.

## Reviewer
- **Overall assessment** The manuscript presents a computational pipeline for identifying potential inhibitors of PfAP2-I, a transcription factor implicated in malaria parasite invasion. The work is methodologically conventional and internally consistent in its narrative, but several critical gaps in evidence and analysis undermine the strength of the central claims. The structure prediction and validation are described with reasonable detail, yet the docking and MD simulation sections lack quantitative rigor and comparative benchmarks. The claim that MCULE-7146940834 is a lead candidate is not fully supported by the data presented, particularly given the absence of a positive control in docking, limited MD analysis, and no experimental validation. The manuscript would benefit from clearer justification of methodological choices, more robust statistical analysis, and a more cautious interpretation of results.
- **Who would be interested in the results, and why** Researchers in computational drug discovery, malariology, and structural biology of *Plasmodium* proteins may find the predicted structure and identified hits of interest as a starting point for further screening or experimental validation. The work also speaks to those studying transcription factors as therapeutic targets, though the lack of experimental confirmation limits its immediate translational relevance.
- **Major strengths** The study addresses a clinically relevant target (PfAP2-I) in the context of antimalarial drug resistance. The use of multiple computational tools (ROBETTA, I-TASSER, AlphaFold comparison, CASTp, Pharmit, AutoDock Vina, MD simulation) reflects a comprehensive in silico approach. The authors are transparent about the lack of an experimental structure and the need for future validation.
- **Major Concerns** See detailed items below.
- **Minor Comments** See detailed items below.
- **Technical failings that need to be addressed before the case is established** R1-M1 (docking validation), R1-M2 (MD simulation rigor), R1-M3 (active site selection), R1-M4 (comparative structure assessment), R1-M5 (data availability)
- **Assessment against Nature-style criteria**  
  - **Originality** Moderate. The application of established in silico methods to a specific target is not conceptually novel, though the target itself is understudied.  
  - **Scientific importance** Moderate. Potential relevance to antimalarial drug discovery, but the lack of experimental validation and limited mechanistic insight reduce immediate impact.  
  - **Interdisciplinary readership** Limited. The work is primarily of interest to computational biologists and malariologists; the presentation is technical and may not engage a broader scientific audience.  
  - **Technical soundness** Weak. Several methodological choices are inadequately justified, and key analyses (docking validation, MD convergence, active site selection) are incomplete or missing.  
  - **Readability for nonspecialists** Poor. The manuscript assumes familiarity with computational techniques and does not provide sufficient context for readers outside the field.  
  Overall, the manuscript does not currently meet the bar for a Nature-style publication due to technical gaps and overinterpretation of results.
- **Recommendation posture** Currently not established from the provided evidence. The manuscript requires substantial revisions, additional analyses, and likely experimental validation before the claims can be considered robust.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** The authors claim that five compounds were identified as high-affinity hits based on docking scores between −8.9 and −11.7 Kcal/mol, and that these are superior to the reference compound and chloroquine.  
- **Evidence pointer** Results section "Pharmacophore-based virtual screening and molecular docking analysis"; Table 4 (not provided)  
- **Concern** The docking results are presented without any validation of the docking protocol. No redocking of a known ligand, cross-docking, or comparison with experimental binding data is described. The absence of a positive control (e.g., a known inhibitor or co-crystallized ligand) makes it impossible to assess whether the docking scores are meaningful or an artifact of the scoring function.  
- **Why it matters** Without validation, the reported binding affinities cannot be interpreted as reliable indicators of inhibitory potential. This is a fundamental requirement for structure-based virtual screening studies.  
- **Resolution test** The authors should perform and report a validation of the docking protocol, such as redocking a known ligand to its cognate structure (if available) or using a decoy set to calculate enrichment factors. They should also justify the choice of AutoDock Vina parameters and grid box dimensions.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** The authors claim that MCULE-7146940834 maintained a stable conformation within the protein’s active site during MD simulation, supporting its potential as an inhibitor.  
- **Evidence pointer** Results section "Molecular dynamic simulation of the lead compound"; Figures 7 and 8 (not provided)  
- **Concern** The MD simulation is described with minimal methodological detail. The simulation time (1000 ps) is very short for assessing binding stability, and no convergence criteria, replicate runs, or free energy calculations (e.g., MM-PBSA) are reported. The RMSD range of 0.020–0.035 Å is suspiciously low for a protein of this size (183 kDa) and may indicate insufficient equilibration or an overly constrained system.  
- **Why it matters** The claim of stable binding is central to the conclusion that MCULE-7146940834 is a lead candidate. Inadequate MD analysis undermines this claim and the overall credibility of the study.  
- **Resolution test** The authors should provide detailed MD parameters, extend the simulation to at least 100 ns, include replicate runs, and report convergence metrics (e.g., RMSD plateau, RMSF analysis, and binding free energy estimates). They should also clarify the force field and solvation model used.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** The authors selected pocket ID 1 from CASTp as the active site for docking, implying it is functionally relevant.  
- **Evidence pointer** Results section "Active site prediction of AP2-I-modeled structure"; Figure 4 (not provided)  
- **Concern** The selection of pocket ID 1 is not justified. No comparison with known functional residues, DNA-binding domains, or conserved motifs is provided. The authors do not demonstrate that this pocket is druggable or biologically relevant.  
- **Why it matters** Docking against an arbitrary pocket can produce false positives. The functional relevance of the chosen site is essential for the validity of the entire screening approach.  
- **Resolution test** The authors should map the predicted pocket onto known functional domains (e.g., AP2 DNA-binding domain) and provide evidence that the pocket is conserved or functionally important. They should also consider docking against multiple pockets and comparing results.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** No  
- **Axis** Scientific importance  
- **Claim pointer** The authors state that the ROBETTA model was prioritized over I-TASSER and AlphaFold based on validation metrics.  
- **Evidence pointer** Results section "Structure validation of modeled proteins"; Tables 1 and 2 (not provided)  
- **Concern** The comparison between models is presented superficially. The authors report ERRAT, Ramachandran, and MolProbity scores for the ROBETTA model but do not provide the corresponding metrics for the I-TASSER and AlphaFold models in the main text. Without a side-by-side comparison, the claim of superiority is not substantiated.  
- **Why it matters** The choice of model affects all downstream analyses. A transparent and quantitative comparison is necessary to justify the selection.  
- **Resolution test** Provide a table comparing all validation metrics (ERRAT, Ramachandran, MolProbity, clashscore) for ROBETTA, I-TASSER, and AlphaFold models, and discuss the implications of any differences.

- **Concern ID** R1-M5  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Reproducibility  
- **Claim pointer** The authors claim that 8115 compounds were screened and five were selected as hits.  
- **Evidence pointer** Results section "Pharmacophore-based virtual screening and molecular docking analysis"; Table 3 (not provided)  
- **Concern** The screening process is not reproducible from the provided information. The pharmacophore model features, the databases used, the selection criteria for the five hits, and the full list of docking scores are not provided. The supplementary tables are referenced but not available.  
- **Why it matters** Reproducibility is a core requirement for computational studies. Without full data and criteria, the screening results cannot be independently verified or compared with other studies.  
- **Resolution test** Provide the pharmacophore model parameters, the complete list of screened compounds with docking scores, and the explicit criteria for selecting the five hits. Ensure supplementary materials are accessible.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Methods section "Molecular dynamic simulation of the lead compound"  
- **Evidence pointer** Location not provided  
- **Issue** The description of the MD simulation is vague. The authors mention "Nose–Poincare–Andersen (NPA) algorithm" but do not explain its relevance or how it was implemented.  
- **Required correction** Provide a clear description of the MD protocol, including the software version, thermostat/barostat settings, and rationale for using the NPA algorithm.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Readability  
- **Affected element** Abstract and Discussion  
- **Evidence pointer** Location not provided  
- **Issue** The abstract and discussion use technical jargon (e.g., "pharmacophore modeling," "postdocking studies") without defining terms for a broader audience.  
- **Required correction** Add brief explanations or context for non-specialist readers, or restructure sentences to improve accessibility.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Data presentation  
- **Affected element** Results section "Post-docking analysis"  
- **Evidence pointer** Figure 5 (not provided)  
- **Issue** The 2D and 3D interaction diagrams are referenced but not described in the text. The authors do not summarize the key interactions (e.g., hydrogen bonds, hydrophobic contacts) for each hit compound.  
- **Required correction** Provide a textual summary of the key interactions for each of the five compounds, highlighting any differences that justify their selection.

- **Concern ID** R1-m4  
- **Severity** Minor  
- **Axis** Completeness  
- **Affected element** Methods section "In silico drug-likeness and toxicity predictions"  
- **Evidence pointer** Location not provided  
- **Issue** The authors do not specify the version or parameters used for SwissADME and OSIRIS Property Explorer, nor do they explain how the "drug score" is calculated.  
- **Required correction** Provide software versions, parameter settings, and a brief explanation of the drug score calculation.

## Risk / unsupported claims
- The claim that MCULE-7146940834 is a "lead candidate" for PfAP2-I inhibition is unsupported without experimental validation and is overstated given the lack of docking validation and short MD simulation.
- The claim that the ROBETTA model is superior to AlphaFold and I-TASSER models is not substantiated because comparative validation metrics are not fully presented.
- The functional relevance of pocket ID 1 as the active site is asserted without evidence linking it to known biological function.
- The statement that the five hits have "good estimated binding energies" is not supported by any benchmark or comparison with known inhibitors.
- The assertion that the MD simulation demonstrates "stable conformation" is not supported by sufficient simulation length, replicates, or free energy analysis.